XML 21 R7.htm IDEA: XBRL DOCUMENT v3.4.0.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Apr. 02, 2016
Mar. 28, 2015
Mar. 29, 2014
Cash Flows from Operating Activities:      
Net (loss) income $ (55,579) $ 16,897 $ 35,148
Non-cash items:      
Depreciation and amortization 89,911 86,053 81,740
Impairment of assets 101,243 5,877 2,587
Stock compensation expense 6,949 14,095 13,082
Deferred tax (benefit) expense (1,038) 4,230 1,736
Unrealized (gain)/loss from hedging activities (2,645) 1,558 (128)
Changes in fair value of contingent consideration (4,727) (2,918) 45
Provision for losses on accounts receivable and inventory 13,053 4,972 3,020
Other non-cash operating activities 899 1,055 5,367
Change in operating assets and liabilities:      
Change in accounts receivable, net (10,328) 8,446 6,063
Change in inventories 11,896 (21,515) (15,613)
Change in prepaid income taxes (651) 10,662 1,175
Change in other assets and other liabilities 3,121 (8,013) 3,176
Tax benefit of exercise of stock options 0 3,786 1,649
Change in accounts payable and accrued expenses (30,239) 1,993 477
Net cash provided by operating activities 121,865 127,178 139,524
Cash Flows from Investing Activities:      
Capital expenditures (102,405) (122,220) (73,648)
Proceeds from sale of property, plant and equipment 637 452 488
Acquisition of Hemerus 0 0 (23,124)
Other acquisitions and investments (3,000) 0 (9,546)
Net cash used in investing activities (104,768) (121,768) (105,830)
Cash Flows from Financing Activities:      
Payments on long-term real estate mortgage (943) (1,048) (964)
Net increase (decrease) in short-term loans 2,272 843 (5,521)
Repayment of term loan borrowings (21,342) (8,531) (37,063)
Proceeds from employee stock purchase plan 4,341 4,763 5,229
Proceeds from exercise of stock options 14,032 9,290 15,225
Share repurchases (60,984) (39,033) 0
Other financing activities 0 556 2,395
Net cash used in financing activities (62,624) (33,160) (20,699)
Effect of exchange rates on cash and cash equivalents (12) (4,057) 354
Net Change in Cash and Cash Equivalents (45,539) (31,807) 13,349
Cash and Cash Equivalents at Beginning of Year 160,662 192,469 179,120
Cash and Cash Equivalents at End of Year 115,123 160,662 192,469
Supplemental Disclosures of Cash Flow Information:      
Interest paid 8,511 8,497 8,942
Income taxes paid 7,829 11,211 7,261
Transfers from inventory to fixed assets for placement of Haemonetics equipment $ 9,663 $ 7,458 $ 10,584